Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C16H14FNO |
| Molecular Weight | 255.2869 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
FC1=CC=C(C=C1)C(=O)NC2CC3=C(C2)C=CC=C3
InChI
InChIKey=BOFMSBVSYVESTM-UHFFFAOYSA-N
InChI=1S/C16H14FNO/c17-14-7-5-11(6-8-14)16(19)18-15-9-12-3-1-2-4-13(12)10-15/h1-8,15H,9-10H2,(H,18,19)
| Molecular Formula | C16H14FNO |
| Molecular Weight | 255.2869 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Tue Apr 01 16:27:42 GMT 2025
by
admin
on
Tue Apr 01 16:27:42 GMT 2025
|
| Record UNII |
9U46KWJ9UF
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
291756-32-6
Created by
admin on Tue Apr 01 16:27:42 GMT 2025 , Edited by admin on Tue Apr 01 16:27:42 GMT 2025
|
PRIMARY | |||
|
9U46KWJ9UF
Created by
admin on Tue Apr 01 16:27:42 GMT 2025 , Edited by admin on Tue Apr 01 16:27:42 GMT 2025
|
PRIMARY | |||
|
10131276
Created by
admin on Tue Apr 01 16:27:42 GMT 2025 , Edited by admin on Tue Apr 01 16:27:42 GMT 2025
|
PRIMARY | |||
|
300000042398
Created by
admin on Tue Apr 01 16:27:42 GMT 2025 , Edited by admin on Tue Apr 01 16:27:42 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
We investigated whether the impaired neovascularization capacity of ICMP patient-derived progenitor cells can be restored by pretreatment
with the novel endothelial NO synthase (eNOS) transcription
enhancer AVE9488 (AVE). Ex vivo pretreatment of BMC from
patients with ICMP with AVE significantly increased eNOS mRNA expression by 2.1-fold (P < 0.05) and eNOS activity as assessed by ESR by >3-fold (P < 0.05). The increased eNOS expression was
associated with an enhanced migratory capacity in vitro (P < 0.01) and improved neovascularization capacity of the infused BMC in an
ischemic hind limb model in vivo (P < 0.001).
|
||
|
ACTIVE MOIETY |
We tested the effects of the eNOS enhancer AVE 9488 on cardiac ischemia/reperfusion injury in vivo in mice. After treatment with the eNOS enhancer AVE 9488 (30 mg/kg/day) or placebo for one week mice underwent 30 min of coronary artery ligation and 24 h of reperfusion in vivo. Ischemia-reperfusion damage was significantly reduced in mice treated with the eNOS enhancer when compared to placebo treated mice (infarct/area at risk 65.4 +/- 4.1 vs. 36.9 +/- 4.0%, placebo vs. eNOS enhancer, P = 0.0002).
|
